Fisher & Paykel Healthcare's challenges in the year ahead to recalibrate after a boom time through Covid has led Forsyth Barr to reiterate its belief the medical device manufacturer's stock is overpriced, with its analysts downgrading the stock to ‘underperform’ from ‘neutral’.
Long a
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
